Felbamate efficacy and tolerability in patients with refractory epilepsy: An open add-on multicentric study.

Abstract

A multicenter study that evaluated felbamate efficacy and tolerability in 19 patients with refractory epilepsy was performed. One patient (5,3%) became seizure-free during felbamate treatment, 11 patients (57,9%) achieved a seizure reduction of 50% or more, 6 patients (31,6%) evidenced an unchanged seizure frequency and 1 patient (5,3%) had increase in seizure frequency. Of the 7 patients (36,8%) who had a diagnosis of Lennox-Gastaut syndrome, 5 (71,4%) had >50% reduction in seizure frequency, 1 (14,2%) had unchanged seizure frequency and 1 (14,2%) had an increase in seizure frequency.